- Jasper Therapeutics Inc (NASDAQ:JSPR) will focus on developing its lead product candidate, briquilimab (formerly JSP191), in chronic diseases and stem cell transplants for rare diseases.
- This portfolio includes a new program on chronic urticaria, along with the company’s existing programs for lower-risk myelodysplastic syndrome (MDS), sickle cell disease, Fanconi anemia, and severe combined immunodeficiency (SCID).
- Based on preclinical and clinical studies showing inhibition of c-Kit signaling and depletion of mast cells, Jasper has prioritized starting a clinical study in severe chronic urticaria.
- While the company has no near-term plans to initiate a Phase 3 study in AML/MDS, it will continue to work with the FDA to explore development pathways and ensure briquilimab remains ready for a pivotal Phase 3 study in AML/MDS stem cell transplant.
- Last week, Jasper Therapeutics announced data from the first three participants in a Phase 1/2 trial of adding briquilimab to an existing bone marrow transplantation regimen in individuals with sickle cell disease and beta-thalassemia.
- Price Action: JSPR shares are up 13.20% at $1.80 on the last check Tuesday.
Warner Bros. Vs. Amazon Vs. Netflix Vs. Disney: Analyst Picks Potential Winners In Streaming Matchups
In the wake of Warner Bros. Discovery, Inc.’s (NASDAQ:WBD) Max streaming event held on Wednesday, an analyst at…
